Intellia Therapeutics financials
$12.03+5.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $15.0M | $23.0M | $13.8M | $14.2M | $16.6M | $12.9M | $9.1M | $7.0M | $28.9M | — | $12.0M |
| Gross profit | $7.7M | $15.0M | $23.0M | $13.8M | $14.2M | $16.6M | $12.9M | $9.1M | $7.0M | $28.9M | — | $12.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Operating income | -$112.8M | -$100.5M | -$98.7M | -$111.5M | -$110.0M | -$120.8M | -$136.4M | -$144.8M | -$139.0M | -$114.0M | — | -$131.1M |
| Net income | -$106.6M | -$96.2M | -$95.8M | -$101.3M | -$101.3M | -$114.3M | -$128.9M | -$135.7M | -$147.0M | -$107.4M | — | -$122.2M |
| Net margin | −1392.3% | −639.5% | −416.2% | −735.2% | −710.8% | −687.6% | −1001.2% | −1489.5% | −2112.6% | −371.3% | — | −1019.2% |
| Diluted EPS | $-0.80 | $-0.81 | $-0.83 | $-0.92 | $-0.98 | $-1.10 | $-1.26 | $-1.34 | $-1.52 | $-1.12 | — | $-1.38 |
| EBITDA | -$110.7M | -$98.3M | -$96.3M | -$109.1M | -$107.5M | -$118.3M | -$133.9M | -$142.2M | -$136.4M | -$111.5M | $0.00 | -$128.8M |
| Operating cash flow | -$83.1M | -$117.3M | -$69.3M | -$76.9M | -$99.6M | -$148.9M | -$85.2M | -$84.8M | -$58.2M | -$120.7M | -$93.1M | -$101.5M |
| Free cash flow | -$84.9M | -$117.4M | -$69.4M | -$76.9M | -$99.9M | -$149.7M | -$86.2M | -$86.1M | -$59.2M | -$123.2M | -$94.6M | -$105.8M |
| Diluted shares | 133.5M | 118.5M | 116.1M | 110.2M | 103.7M | 103.5M | 101.9M | 101.0M | 97.0M | 95.5M | 90.5M | 88.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $106.1M | $134.7M | $155.5M | $193.4M | $156.2M | $126.9M |
| Short-term investments | $331.6M | $241.3M | $294.4M | $317.7M | $303.5M | $376.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $857.2M | $758.8M | $842.1M | $925.3M | $898.9M | $986.2M |
| Total liabilities | $129.5M | $137.8M | $170.7M | $176.9M | $183.6M | $206.2M |
| Shareholders' equity | $727.7M | $620.9M | $671.4M | $748.4M | $715.3M | $779.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology